Week in Review: BeiGene Signs $540 Million Deal for China Rights to Three HBV Candidates

Deals and Financings • Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B from Assembly Bio in a $540 million agreement; • Shanghai HaiHe Biopharma completed a $171 million Series C round to advance its portfolio of ten innovative drugs; • Jiangsu Hansoh Pharma out-licensed ex-China for almonertinib, its lung cancer treatment, to EQRx™ of Cambridge, MA in a $100 million deal; • Shanghai Antengene closed a $97 million Series C financing to support its portfolio of 12 hematology and oncology candidates; • Thousand Oaks Bio, a China-US CDMO that offers GMP cell culture media and biomanufacturing services, announced a $64 million Series B round; • CASI Pharma, a US biopharma developing products for China, raised $38 million in a private placement of its common stock; • Xpect Vision Technology closed a $21 million Series B+ round to support its photon-counting X-ray imaging products for healthcare and industrial uses; • Stroke Medical, a Shanghai company that makes minimally invasive products to treat and prevent strokes, completed a $10 million Series C round; • JW Therapeutics, a Shanghai JV formed by Seattle's Juno and China CRO WuXi AppTec, acquired Syracuse Biopharma of Hong Kong, a cell therapy company; Coronavirus Pandemic • Tianjin's CanSino Bio published positive early results from a Phase II trial of its COVID-19 vaccine showing response in 85% of the participants; Trials and Approvals • Ascentage Pharma of Suzhou began dosing patients in a China Phase Ib trial of its novel MDM2-p53 inhibitor for hematologic malignancies; • N.B. Quadriga of Shanghai and Nantong announced the first patient was dosed in a Australian Phase I trial of its novel brain cancer drug; • Hutchison China MediTech (Chi-Med) started a China Phase I trial of HMPL-306 of a novel treatment for hematological malignancies. Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: ASMB) (HK: 3692) (NSDQ: CASI) (HK: 6185) (HK: 6855) (NSDQ/AIM: HCM) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.